alexa Abstract | Angiotensin Receptor Antagonists A New Class Of Antihypertensive Drugs

Indian Journal of Pharmaceutical Sciences
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article Open Access


Losartan is an orally active, non-peptide Angiotensin II (AT1specific) antagonist. It is a new and promising antihypertesive agent, better than ACE inhibitors in controlling hypertesion. Its antihypertensive effect is enhanced when given in combination with hydrochlorthiazide (HCT) or an ACE inhibitor. Among other angiotensin receptor antagonists are TCV- 116, CV-11974, and CV-11194, all of which seem to be promising antihypertensives of the future. Results of the studies on losartan and other angiotensin receptor antagonists indicate that they would certainly acquire a commanding position in the treatment of hypertension, a disease that makes millions of people suffer.

To read the full article Peer-reviewed Article PDF image

Author(s): Zeenat S Hakim Milan C Satia Ramesh K Goyal

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version